Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission
Applied Therapeutics (Nasdaq: APLT) has filed Form 12b-25 with the SEC, requesting a 15-day extension for submitting its 2024 Annual Report on Form 10-K. The clinical-stage biopharmaceutical company, which develops novel drug candidates for high unmet medical needs, was originally required to file by March 31, 2025.
The company is currently working to finalize its financial statements and expects to file the report by April 15, 2025, the deadline of the extension period. Applied Therapeutics will announce its Q4 and full-year 2024 earnings results once the Form 10-K filing date is confirmed.
Applied Therapeutics (Nasdaq: APLT) ha presentato il modulo 12b-25 alla SEC, richiedendo un'estensione di 15 giorni per la presentazione del suo Rapporto Annuale 2024 sul modulo 10-K. L'azienda biofarmaceutica in fase clinica, che sviluppa nuovi candidati farmaci per esigenze mediche elevate non soddisfatte, doveva inizialmente presentare il rapporto entro il 31 marzo 2025.
L'azienda sta attualmente lavorando per finalizzare i suoi bilanci e prevede di presentare il rapporto entro il 15 aprile 2025, scadenza del periodo di estensione. Applied Therapeutics annuncerà i risultati del quarto trimestre e dell'intero anno 2024 non appena la data di presentazione del modulo 10-K sarà confermata.
Applied Therapeutics (Nasdaq: APLT) ha presentado el formulario 12b-25 ante la SEC, solicitando una extensión de 15 días para presentar su Informe Anual 2024 en el formulario 10-K. La empresa biofarmacéutica en etapa clínica, que desarrolla nuevos candidatos a medicamentos para necesidades médicas no satisfechas, originalmente debía presentar el informe antes del 31 de marzo de 2025.
La empresa está trabajando actualmente para finalizar sus estados financieros y espera presentar el informe antes del 15 de abril de 2025, la fecha límite del período de extensión. Applied Therapeutics anunciará sus resultados del cuarto trimestre y del año completo 2024 una vez que se confirme la fecha de presentación del formulario 10-K.
Applied Therapeutics (Nasdaq: APLT)는 SEC에 12b-25 양식을 제출하고 2024년 연례 보고서 10-K 제출을 위해 15일 연장을 요청했습니다. 높은 미충족 의료 수요를 위한 새로운 약물 후보를 개발하는 임상 단계의 생명공학 회사는 원래 2025년 3월 31일까지 제출해야 했습니다.
회사는 현재 재무 제표를 마무리하고 있으며, 연장 기간의 마감일인 2025년 4월 15일까지 보고서를 제출할 것으로 예상하고 있습니다. Applied Therapeutics는 10-K 양식 제출 날짜가 확인되면 2024년 4분기 및 전체 연도 실적을 발표할 것입니다.
Applied Therapeutics (Nasdaq: APLT) a déposé le formulaire 12b-25 auprès de la SEC, demandant une extension de 15 jours pour soumettre son Rapport Annuel 2024 sur le formulaire 10-K. L'entreprise biopharmaceutique en phase clinique, qui développe de nouveaux candidats médicaments pour des besoins médicaux non satisfaits, devait initialement soumettre le rapport d'ici le 31 mars 2025.
L'entreprise travaille actuellement à finaliser ses états financiers et s'attend à soumettre le rapport d'ici le 15 avril 2025, date limite de la période d'extension. Applied Therapeutics annoncera ses résultats du quatrième trimestre et de l'année complète 2024 une fois que la date de soumission du formulaire 10-K sera confirmée.
Applied Therapeutics (Nasdaq: APLT) hat das Formular 12b-25 bei der SEC eingereicht und eine 15-tägige Verlängerung für die Einreichung seines Jahresberichts 2024 im Formular 10-K beantragt. Das biopharmazeutische Unternehmen in der klinischen Phase, das neuartige Arzneimittelkandidaten für hohe unbefriedigte medizinische Bedürfnisse entwickelt, war ursprünglich verpflichtet, bis zum 31. März 2025 einzureichen.
Das Unternehmen arbeitet derzeit daran, seine Finanzberichte abzuschließen, und erwartet, den Bericht bis zum 15. April 2025, dem Fristende der Verlängerung, einzureichen. Applied Therapeutics wird seine Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 bekannt geben, sobald das Datum der Einreichung des Formulars 10-K bestätigt ist.
- None.
- Delay in filing annual financial reports indicates potential internal financial reporting complications
- Uncertainty around Q4 and full-year 2024 financial results timing
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission (“SEC”) related to the Company’s Annual Report on Form 10-K for the fiscal year 2024 (the “Form 10-K”). Form 12b-25 will allow the Company an automatic extension of 15 additional calendar days to file the Form 10-K for the fiscal year 2024, which is due on March 31, 2025. The Company is working diligently to finalize its financial statements and currently expects to file its Annual Report on Form 10-K as soon as practicable by April 15, 2025, the end of the 15-day extension period, in accordance with Rule 12b-25.
The 12b-25 filing is available on Applied’s Investor Relations website at https://ir.appliedtherapeutics.com/ under “SEC Filings” on the “Financial Info” page.
The Company will make a subsequent announcement to disclose its fourth quarter and full-year 2024 earnings results once the filing date of its Form 10-K is confirmed.
About Applied Therapeutics
Applied Therapeutics is a clinical-stage biopharmaceutical company committed to the development of novel drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (“ARI”) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Sorbitol Dehydrogenase (“SORD”) Deficiency and PMM2-congenital disorder glycosylation (“CDG”).
To learn more, please visit www.appliedtherapeutics.com and follow the company on X at @Applied_Tx.
Forward-Looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding the strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “plan,” “intend,” “predicts” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are forward-looking statements. These include, without limitation, statements regarding the anticipated timing for the filing of the Company’s Form 10-K. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved.
Such risks and uncertainties include, without limitation, (i) our plans to develop, market and commercialize our product candidates, (ii) the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and our research and development programs, (iii) our ability to take advantage of expedited regulatory pathways for any of our product candidates, (iv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing, (v) our ability to successfully acquire or license additional product candidates on reasonable terms and advance product candidates into, and successfully complete, clinical studies, (vi) our ability to maintain and establish collaborations or obtain additional funding, (vii) our ability to obtain and timing of regulatory approval of our current and future product candidates, (viii) the anticipated indications for our product candidates, if approved, (ix) our expectations regarding the potential market size and the rate and degree of market acceptance of such product candidates, (x) our ability to fund our working capital requirements and expectations regarding the sufficiency of our capital resources, (xi) the implementation of our business model and strategic plans for our business and product candidates, (xii) our intellectual property position and the duration of our patent rights, (xiii) developments or disputes concerning our intellectual property or other proprietary rights, (xiv) our expectations regarding government and third-party payor coverage and reimbursement, (xv) our ability to compete in the markets we serve, (xvi) the impact of government laws and regulations and liabilities thereunder, (xvii) developments relating to our competitors and our industry, (xviii) our ability to achieve the anticipated benefits from the agreements entered into in connection with our partnership with Advanz Pharma and (xiv) other factors that may impact our financial results. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including those described in the “Risk Factors” section contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Contacts
Investors:
Maeve Conneighton / Andrew Vulis
(212) 600-1902
appliedtherapeutics@argotpartners.com
Media:
media@appliedtherapeutics.com
FAQ
When will Applied Therapeutics (APLT) file its 2024 Annual Report?
Why did Applied Therapeutics (APLT) delay its 2024 Form 10-K filing?
When will APLT release its Q4 and full-year 2024 earnings?
What is the significance of Form 12b-25 filed by Applied Therapeutics?
